Skip header and navigation

2 records – page 1 of 1.

Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.

https://arctichealth.org/en/permalink/ahliterature54237
Source
Am Heart J. 1999 Jun;137(6):1062-9
Publication Type
Article
Date
Jun-1999
Author
B L Nørgaard
K. Wachtell
P D Christensen
B. Madsen
J B Johansen
E H Christiansen
O. Graff
E H Simonsen
Author Affiliation
Aarhus University Hospital, Aarhus, Denmark.
Source
Am Heart J. 1999 Jun;137(6):1062-9
Date
Jun-1999
Language
English
Publication Type
Article
Keywords
Aged
Anti-Arrhythmia Agents - administration & dosage - adverse effects - pharmacokinetics
Atrial Fibrillation - blood - drug therapy - physiopathology
Atrial Flutter - blood - drug therapy - physiopathology
Denmark
Double-Blind Method
Female
Hemodynamic Processes - drug effects
Humans
Infusions, Intravenous
Male
Middle Aged
Phenethylamines - administration & dosage - adverse effects - pharmacokinetics
Placebos
Potassium Channel Blockers
Prospective Studies
Safety
Sulfonamides - administration & dosage - adverse effects - pharmacokinetics
Time Factors
Abstract
BACKGROUND: This study was designed to assess the efficacy and safety of intravenous dofetilide in acute termination of atrial fibrillation (AF) and flutter (AFL). Dofetilide, an investigational class III antiarrhythmic agent, selectively inhibits the rapid component of the delayed rectifier potassium current, thus prolonging the effective refractory period and duration of the action potential. Dofetilide can be administered intravenously and has a rapid onset of electrophysiologic action. METHODS AND RESULTS: Ninety-six patients with AF (n = 79) or AFL (n = 17) with a median arrhythmia duration of 62 days (range 1 to 180) were randomized to placebo (n = 30) or 8 micrograms/kg IV dofetilide (n = 66) over 30 minutes. Conversion was defined as termination of the atrial arrhythmia within 3 hours from the start of infusion. The conversion rate was 30.3% after dofetilide and 3.3% after placebo (P
Notes
Comment In: Am Heart J. 1999 Jun;137(6):992-510347318
PubMed ID
10347332 View in PubMed
Less detail

[Treatment with implantable cardioverter-defibrillators. Experiences from Skejby hospital during the period 1989-1994]

https://arctichealth.org/en/permalink/ahliterature54685
Source
Ugeskr Laeger. 1996 Feb 19;158(8):1068-72
Publication Type
Article
Date
Feb-19-1996
Author
J C Nielsen
E H Christiansen
P T Mortensen
A K Pedersen
Author Affiliation
Hjertemedicinsk afdeling B, Skejby Sygehus, Arhus.
Source
Ugeskr Laeger. 1996 Feb 19;158(8):1068-72
Date
Feb-19-1996
Language
Danish
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Defibrillators, Implantable
Denmark - epidemiology
English Abstract
Female
Follow-Up Studies
Humans
Male
Middle Aged
Tachycardia, Ventricular - mortality - physiopathology - therapy
Abstract
The aim of the present study was to evaluate survival and therapy for ventricular tachyarrhythmia in patients treated with implantable cardioverter-defibrillator (ICD)-implantation at Skejby Hospital. Seventy-two patients, of which 54 were male, have received an ICD since 1989. Mean (range) age was 54 (16-74) years. Forty-nine (68%) had ischaemic heart disease. The patients were followed for a median (range) of 14 (1/2-50) months. Kaplan-Meyer plots are presented for total mortality, cardiac mortality, sudden cardiac mortality, appropriate therapy, and therapy for life-threatening tachyarrhythmia. After one, two and three years respectively, mortality was respectively 13, 27, and 32%, cardiac mortality was 5, 19, and 24%, sudden cardiac mortality was 3, 6, and 12%, cumulative incidence of appropriate therapy was 56, 66, and 90%, and cumulative incidence of therapy for life-threatening tachyarrhythmia was 19, 29 and 52%. It is concluded, that the majority of patients treated with an ICD developed ventricular tachyarrhythmia and had appropriate or lifesaving ICD-therapy during follow-up.
PubMed ID
8638339 View in PubMed
Less detail